Scope International

Executive Summary

Scope International AG is a German full-service Contract Research Organization (CRO) founded in 2000, with over 300 clinical studies conducted across 30 countries. The company provides tailored Phase I-IV services, including clinical operations, data management, and regulatory affairs, adhering to global standards. As a private entity, Scope International emphasizes flexibility and quality, positioning itself as a reliable partner for pharmaceutical and biotech clients. The CRO market is growing, driven by increasing R&D outsourcing. Scope International's established track record and geographic reach provide a competitive advantage. However, limited public financials and pipeline visibility constrain conviction. Financially, the company's private status means no public disclosures, making detailed assessment difficult. The business model is service-based, with recurring revenues from ongoing studies. Overall, Scope International appears as a stable, mid-tier CRO with potential for steady growth, but lacking near-term disruptive catalysts.

Upcoming Catalysts (preview)

• Q4 2026Major new contract win with top pharma company50% success
• Q2 2027Expansion into Asian or North American markets30% success
• Q3 2026Achievement of ISO or regulatory accreditation upgrade70% success